Viracta Therapeutics’ (VIRX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Viracta Therapeutics (NASDAQ:VIRX) in a research report sent to investors on Tuesday, Benzinga reports. The firm currently has a $4.00 price target on the stock.

Viracta Therapeutics Trading Down 8.4 %

NASDAQ:VIRX opened at $0.71 on Tuesday. The firm has a market cap of $28.07 million, a price-to-earnings ratio of -0.54 and a beta of 0.93. The company’s 50-day moving average is $0.89 and its two-hundred day moving average is $0.70. Viracta Therapeutics has a 12-month low of $0.43 and a 12-month high of $2.38.

Viracta Therapeutics (NASDAQ:VIRX) last posted its quarterly earnings data on Thursday, March 7th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.05). On average, equities research analysts forecast that Viracta Therapeutics will post -1.28 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of VIRX. Millennium Management LLC acquired a new position in shares of Viracta Therapeutics during the 2nd quarter valued at about $1,227,000. Vanguard Group Inc. increased its stake in shares of Viracta Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,114,368 shares of the company’s stock valued at $4,759,000 after acquiring an additional 207,108 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of Viracta Therapeutics during the 3rd quarter valued at about $625,000. BlackRock Inc. increased its stake in shares of Viracta Therapeutics by 22.2% during the 3rd quarter. BlackRock Inc. now owns 662,600 shares of the company’s stock valued at $2,830,000 after acquiring an additional 120,169 shares during the last quarter. Finally, Two Sigma Investments LP acquired a new stake in Viracta Therapeutics during the 4th quarter worth approximately $87,000. Institutional investors and hedge funds own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.